

Lifetime Probability of Developing and Dying from Cancer, 2013-2015

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
All Sites*	39.3	3	21.7	5	37.7	3	18.5	5
Brain & ONS	0.7	146	0.5	191	0.5	182	0.4	240
Breast	0.1	814	<0.1	3,115	12.4	8	2.6	39
Colorectal	4.4	23	1.9	53	4.1	25	1.7	59
Esophagus	0.8	133	0.8	132	0.2	449	0.2	502
Hodgkin lymphoma	0.2	434	<0.1	2,507	0.2	557	<0.1	3,454
Kidney & renal pelvis	2.1	47	0.6	163	1.2	82	0.3	301
Larynx	0.5	191	0.2	516	0.1	823	<0.1	2,177
Leukemia	1.8	56	1.0	101	1.3	80	0.7	145
Liver & intrahepatic bile duct	1.4	70	1.0	99	0.6	162	0.5	191
Lung & bronchus	6.7	15	5.7	17	5.9	17	4.6	22
Melanoma of skin†	3.7	27	0.5	198	2.5	40	0.2	404
Myeloma	0.9	113	0.5	210	0.7	151	0.4	261
Non-Hodgkin lymphoma	2.4	42	0.8	121	1.9	54	0.6	155
Oral cavity & pharynx	1.6	61	0.4	245	0.7	145	0.2	554
Ovary	--	--	--	--	1.3	79	0.9	111
Pancreas	1.6	62	1.4	72	1.6	65	1.3	74
Prostate	11.2	9	2.4	41	--	--	--	--
Stomach	1.0	97	0.5	219	0.6	156	0.3	329
Testis	0.4	250	<0.1	5,204	--	--	--	--
Thyroid	0.6	156	<0.1	1,758	1.8	55	<0.1	1,421
Urinary bladder‡	3.7	27	0.9	107	1.1	91	0.3	291
Uterine cervix	--	--	--	--	0.6	162	0.2	447
Uterine corpus	--	--	--	--	2.9	35	0.6	163

*All sites excludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

†Statistics are for non-Hispanic whites.

‡Includes invasive and in situ cancer cases.

Source: Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.6, National Cancer Institute, 2018.